Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2/3 1Phase 1/2 1

Status

Completed 55Terminated 19Recruiting 8Unknown 6Not yet recruiting 3Active not recruiting 3

Sponsor Class

NIH 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gynecologic 3

Conditions

Small Cell Lung Carcinoma 8Neuroblastoma 5Rhabdoid Tumor 3Ovarian Neoplasms 3Neoplasms 3Fallopian Tube Neoplasms 3Neoplasm Metastasis 2Uterine Cervical Neoplasms 1Thrombocythemia, Essential 1Sarcoma, Ewing 1Sarcoma 1SCLC 1Rhabdomyosarcoma 1Retinoblastoma 1Recurrence 1Primary Myelofibrosis 1Polycythemia Vera 1Pancreatic Neoplasms 1Myelodysplastic-Myeloproliferative Diseases 1Medulloblastoma 1Lung Neoplasms 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 1Leukemia, Myeloid, Acute 1Fallopian Tube Mucinous Adenocarcinoma 1Epilepsy 1Diffuse Intrinsic Pontine Glioma 1Choroid Plexus Neoplasms 1Central Nervous System Neoplasms 1Carcinoma, Neuroendocrine 1

Interventions

pembrolizumab 24Carboplatin 21Paclitaxel 20olaparib 19Magnetic Resonance Spectroscopy 14Bevacizumab 14Cyclophosphamide 12Specimen Handling 11Nivolumab 11Gemcitabine 11Taxes 10niraparib 8Cisplatin 8Biopsy 8liposomal doxorubicin 7fludarabine 7Surveys and Questionnaires 6Immunoglobulin G 6Doxorubicin 6Disulfides 6durvalumab 5palbociclib 4oregovomab 4X-Rays 4Ipilimumab 4mirvetuximab soravtansine 3ipatasertib 3defactinib 3cediranib 3atezolizumab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Active not recruiting × Ovarian Neoplasms × Topotecan × Clear all
NCT06619236 2026-06-02

RAINFOL-02

Genmab

Phase 3 Active not recruiting
448 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT01012817 2026-04-29

Veliparib and Topotecan Hydrochloride in Treating Patients With Solid Tumors, Relapsed or Refractory Ovarian Cancer, or Primary Peritoneal Cancer

National Cancer Institute (NCI)

Phase 1/2 Active not recruiting
88 enrolled 23 charts
Gynecologic

Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms

NCT02502266 2026-04-29

Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer

National Cancer Institute (NCI)

Phase 2/3 Active not recruiting
582 enrolled 21 charts
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡